PVH
62
-6
EW
36
-4
EXPD
39
-6
MTCH
44
-6
HCA
48
-2
C
44
-3
JWN
60
-5
APH
70
-4
WFC
55
-3
EXR
39
-5
LH
48
-5
FFIV
55
-11
FITB
53
-6
AMG
33
-2
PH
70
-7
MRK
66
-3
MHK
50
-5
DG
28
4
KLAC
63
-5
PRGO
59
-5
PVH
62
-6
EW
36
-4
EXPD
39
-6
MTCH
44
-6
HCA
48
-2
C
44
-3
JWN
60
-5
APH
70
-4
WFC
55
-3
EXR
39
-5
LH
48
-5
FFIV
55
-11
FITB
53
-6
AMG
33
-2
PH
70
-7
MRK
66
-3
MHK
50
-5
DG
28
4
KLAC
63
-5
PRGO
59
-5
Financhill
Back

Denali Therapeutics Quote, Financials, Valuation and Earnings

MarketBeat Alert: Escape the market madness with 7 stocks to buy and hold

The result is a select group of high-quality blue-chip stocks.
Sell
24

DNLI
Denali Therapeutics

Last Price:
16.15
Seasonality Move:
-0.16%

7 Day Trial

ALL ACCESS PASS

$ 7

He cracked the code to crypto

Now he says a new two-year bull market has begun. And he likes one altcoin above all others.

Denali Therapeutics Price Quote

$16.15
+0.71 (+4.6%)
(Updated: May 1, 2024 at 6:25 PM ET)

Denali Therapeutics Key Stats

Sell
24
Denali Therapeutics (DNLI) is a Sell
Day range:
$15.21 - $15.58
52-week range:
$14.56 - $33.31
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6.27
P/B ratio:
2.13%
Volume:
715.4K
Avg. volume:
1.1M
1-year change:
-37.84%
Market cap:
$2.2B
Revenue:
$330.5M
EPS:
$-1.08

How Much Does Denali Therapeutics Make?

Data Unavailable

Is Denali Therapeutics Growing As A Company?

Data Unavailable

Denali Therapeutics Stock Price Performance

What Is Denali Therapeutics 52-Week High & Low?

Denali Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Denali Therapeutics?

Is Denali Therapeutics Cash Flow Positive?

  • What Is DNLI Cash Flow From Operations?
    Cash flow from operations (TTM) is -$358M
  • What Is Denali Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $17.8M
  • What Is Denali Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $249.3M

Denali Therapeutics Return On Invested Capital

Data Unavailable

Denali Therapeutics Earnings Date & Stock Price

Denali Therapeutics Competitors

  • Who Are Denali Therapeutics's Competitors?
    Below is a list of companies who compete with Denali Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Halozyme Therapeutics Inc (HALO)
    • Protalix BioTherapeutics Inc (PLX)

Denali Therapeutics Dividend Yield

Data Unavailable

Denali Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -10.08%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 40.27
Upside from Last Price: 160.79%

Major Shareholders

  • How many DNLI shares are owned by institutional investors?
    178.4M DNLI shares are owned by institutional investors
  • How many DNLI shares are owned by insiders?
    2.9M DNLI shares are owned by insiders